Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Boehringer Ingelheim19,805 enrolled

Overview

This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the control of blood pressure in the morning before intake of the next antihypertensive drug

Study Type

OBSERVATIONAL

Enrollment

19,805

Conditions

Hypertension

Interventions

Micardis®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Essential hypertension * At least 18 years of age Exclusion Criteria: * NA

Outcomes

Primary Outcomes

Change from baseline in blood pressure

with special emphasis on the morning blood pressure, before intake of the next antihypertensive treatment

Time frame: Baseline, after 3 months

Number of patients with adverse events

Time frame: up to 3 months

Changes from baseline in pulse rate

Time frame: Baseline, after 3 months

Secondary Outcomes

Assessment of efficacy by investigator on 5- point scale

Time frame: after 3 months

Assessment of tolerability by investigator on a 5-point scale

Time frame: after 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.